A case of glyburide-induced leukocytoclastic vasculitis.

INTRODUCTION Medication-induced leukocytoclastic vasculitis is a small-vessel vasculitis that most commonly manifests with palpable purpuric lesions on gravity dependent areas. Development of the vasculitis occurs within weeks after the initial administration of the medication, with clearance upon withdrawal of the medication. Glyburide, a sulfonylurea medication, is used to treat non-insulin dependent diabetes mellitus. We report a rare case of glyburide-associated leukocytoclastic vasculitis. OBSERVATION We report a 71-year-old man with type 2 diabetes mellitus who presented with palpable purpura on the lower extremities. Cutaneous biopsy revealed superficial small vessel vasculitis with IgA perivascular deposits. Further questioning revealed three prior episodes of palpable purpura after restarting the glyburide medication, with clearance upon discontinuation. We diagnosed drug-induced vasculitis related to the glyburide. CONCLUSIONS This case highlights a rarely reported cutaneous adverse reaction to the commonly used diabetic medication, glyburide. Physicians should consider cutaneous vasculitis as a potential side effect of glyburide.

[1]  M. Radić,et al.  Drug-induced vasculitis: a clinical and pathological review. , 2012, The Netherlands journal of medicine.

[2]  A. Bircher,et al.  Delayed cutaneous manifestations of drug hypersensitivity. , 2010, The Medical clinics of North America.

[3]  A. Wiik Drug-induced vasculitis , 2008, Current opinion in rheumatology.

[4]  H. Hmouda,et al.  Glimepiride-induced vasculitis: a case report. , 2007, British journal of clinical pharmacology.

[5]  S. Vasoo Drug-induced lupus: an update , 2006, Lupus.

[6]  A. Wiik Clinical and laboratory characteristics of drug-induced vasculitic syndromes , 2005, Arthritis research & therapy.

[7]  R. Cheney,et al.  Leukocytoclastic vasculitis induced by use of glyburide: a case of possible cross-reaction of a sulfonamide and a sulfonylurea. , 2003, Cutis.

[8]  R. Falk,et al.  Cutaneous and Systemic Manifestations of Drug-Induced Vasculitis , 2002, The Annals of pharmacotherapy.

[9]  M. Feldmann,et al.  Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. , 2000, Arthritis and rheumatism.

[10]  P. Merkel,et al.  Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. , 2000, Arthritis and rheumatism.

[11]  B. Adams,et al.  Glipizide-induced pigmented purpuric dermatosis. , 1999, Journal of the American Academy of Dermatology.

[12]  K. Hiromura,et al.  Case of propylthiouracil-induced vasculitis associated with anti-neutrophil cytoplasmic antibody (ANCA); review of literature. , 1997, Clinical nephrology.

[13]  I. D. Sanusi,et al.  Enalapril-associated erythema and vasculitis. , 1993, Cutis.

[14]  J. Uetrecht,et al.  Drug metabolism by leukocytes and its role in drug-induced lupus and other idiosyncratic drug reactions. , 1990, Critical reviews in toxicology.

[15]  R. Gradini,et al.  Procainamide-induced urticarial vasculitis. , 1988, Cutis.